Anti-CTLA-4 [9H10]
Ab00894-2.3
ApplicationsFlow Cytometry, Western Blot, ELISA, Neutralisation/Blocking
Product group Antibodies
ReactivityMouse
TargetCtla4
Overview
- SupplierAbsolute Antibody
- Product NameAnti-CTLA-4 [9H10]
- Delivery Days Customer7
- Antibody SpecificityThis antibody is specific for murine CTLA-4, an inhibitory receptor that acts as the primary negative regulator of T-cell responses. CTLA-4 is expressed predominantly by activated T cells, with significantly higher levels of expression on CD8+ T cells tha
- Application Supplier NoteCTLA-4 is upregulated on T cells following their activation, and acts as a negative regulator of T cell responses; CTLA-4 binds to the B7 molecules CD80 and 86, resulting in the delivery of an inhibitory signal, and consequent downregulation of T cell-mediated immunity. Administration of 9H10 blocks the interaction between CTLA-4 on the T cell surface and CD80 and CD86. This promotes the activation of effector T cells and stimulates the immune response raised against weak antigens, including tumour antigens. While this antibody alone does not enhance T cell proliferation, it does significantly increase T cell proliferation when administered together with anti-CD28 (clone 37.51) (Krummel & Allison, 1995), anti-OX40 and anti-GITR (Houot & Levy, 2009). Blocking CTLA-4 induces T cell anti-tumour immunity in animal models, both by suppressing regulatory T cell activity and directly promoting CD8+ T cell effector function (Peggs et al, 2009). In transgenic murine models of prostate cancer, the use of a CTLA-4 blockade in conjunction with an irradiated tumour cell vaccine stimulates an immune response against primary tumours, and results in a significant reduction in tumour incidence (Hurwitz et al, 2000). Similarly, in murine melanoma models, CTLA-4 blockage, in combination with CD40 stimulation and adenoviral vaccination, can elicit complete regression (Sorensen et al, 2010). In murine models of pancreatic ductal adenocarcinoma, 9H10 has also been shown to induce T cell-dependent tumour regressions (Vonderheide et al, 2015). Priming the T cell response with CD40 mAbs or chemotherapy reversed the resistance to 9H10 and RMP1-14 observed in well-established tumours. Additionally, this antibody has been used to detect CTLA-4 using ELISA (Krummel & Allison, 1995) and to stain CTLA-4-expressing cells (Deeths et al, 1999).
- ApplicationsFlow Cytometry, Western Blot, ELISA, Neutralisation/Blocking
- Applications SupplierNeutralisation; WB; FC; ELISA; proliferation assays
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID9H10
- Gene ID12477
- Target nameCtla4
- Target descriptioncytotoxic T-lymphocyte-associated protein 4
- Target synonymsCd152; CD152 antigen; Ctla; Ctla-4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte-associated antigen 4; Ly-5; Ly-56
- HostMouse
- IsotypeIgG2a
- Protein IDP09793
- Protein NameCytotoxic T-lymphocyte protein 4
- Scientific DescriptionThis chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG2 format, for improved compatibility with existing reagents, assays and techniques.
- ReactivityMouse
- Reactivity SupplierMouse
- Reactivity Supplier NoteThis antibody was raised by immunising Syrian hamsters with Staphylococcus A bacteria coated in CTLA-4, isolating B cells from the immunised hamsters and fusing these with the P3X3.Ag8.653 myeloma line to produce stable hybridomas.
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352203